Cart
sales@molnova.com
INO-1001
CAS No. 3544-24-9
INO-1001( 3-Aminobenzamide | INO1001 | INO 1001 )
Catalog No. M14208 CAS No. 3544-24-9
INO-1001 is a potent, selective poly(ADP-ribose) polymerase (PARP) with IC50 of <50 nM in CHO cells.
INO-1001 is a potent, selective poly(ADP-ribose) polymerase (PARP) with IC50 of <50 nM in CHO cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | 33 | In Stock |
|
| 200MG | 43 | In Stock |
|
| 500MG | 73 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameINO-1001
-
NoteResearch use only, not for human use.
-
Brief DescriptionINO-1001 is a potent, selective poly(ADP-ribose) polymerase (PARP) with IC50 of <50 nM in CHO cells.
-
DescriptionINO-1001 is a potent, selective poly(ADP-ribose) polymerase (PARP) with IC50 of <50 nM in CHO cells; significantly radiosensitizes human and rodent cell lines at 10 uM (enhancement ratios 1.4-1.6), enhances radiation-induced cell killing by interfering with DNA repair mechanisms, resulting in necrotic cell death; attenuates various aspects of the pathophysiological response in a clinically relevant experimental model of burn/smoke inhalation injury.Brain Cancer Discontinued(In Vitro):3-Aminobenzamide (PARP-IN-1) (>1 μM) causes more than 95% inhibition of PARP activity without significant cellular toxicity. INO-1001 significantly sensitizes CHO cells by blocking most of the DNA repair occurring between radiation fractions. 3-Aminobenzamide significantly improves endothelial function by enhancing the acetylcholine-induced, endothelium-dependent, nitric oxide mediated vasorelaxation after exposure with 400 μM H2O2.(In Vivo):In a db/db (Leprdb/db) mouse model, 3-Aminobenzamide ameliorates diabetes-induced albumin excretion and mesangial expansion, and also decreases diabetes-induced podocyte depletion. 3-Aminobenzamide (1.6 mg/kg via intracerebral injection) prevents NAD+ depletion and improves water maze performance after controlled cortical impact (CCI) in mice.
-
In Vitro3-Aminobenzamide (PARP-IN-1) (>1 μM) causes more than 95% inhibition of PARP activity without significant cellular toxicity. INO-1001 significantly sensitizes CHO cells by blocking most of the DNA repair occurring between radiation fractions.?3-Aminobenzamide significantly improves endothelial function by enhancing the acetylcholine-induced, endothelium-dependent, nitric oxide mediated vasorelaxation after exposure with 400 μM H2O2.
-
In VivoIn a db/db (Leprdb/db) mouse model, 3-Aminobenzamide ameliorates diabetes-induced albumin excretion and mesangial expansion, and also decreases diabetes-induced podocyte depletion. 3-Aminobenzamide (1.6 mg/kg via intracerebral injection) prevents NAD+ depletion and improves water maze performance after controlled cortical impact (CCI) in mice.
-
Synonyms3-Aminobenzamide | INO1001 | INO 1001
-
PathwayCancer
-
TargetBrain Cancer
-
RecptorPARP
-
Research AreaCancer
-
IndicationBrain Cancer
Chemical Information
-
CAS Number3544-24-9
-
Formula Weight136.1512
-
Molecular FormulaC7H8N2O
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESNC(=O)C1=CC(N)=CC=C1
-
Chemical NameBenzamide, 3-amino-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Shimoda K, et al. Am J Physiol Lung Cell Mol Physiol. 2003 Jul;285(1):L240-9.
2. Szabó G, et al. Shock. 2004 May;21(5):426-32.
3. Du X, et al. J Clin Invest. 2003 Oct;112(7):1049-57.
4. Brock WA, et al. Cancer Lett. 2004 Mar 18;205(2):155-60.
molnova catalog
related products
-
Sulfatinib (b)
Sulfatinib (HMPL-012) is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1/2/3, FGFR1, CSF1R with IC50 of 2/24/1 nM, 15 nM, 4 nM, respectively.
-
Prinomastat
Prinomastat (AG3340) is a potent, selective MMP inhibitor with pM affinities for inhibiting gelatinases (MMP-2 and -9, Ki=50-150 pM).
-
Perifosine
A oral bioavailable alkylphospholipid that displays significant antiproliferative activity in vitro and in vivo in several human tumor model; acts as an Akt inhibitor and a PI3K inhibitor.
